Monomethyl Fumarate
Parkinson Disease (PD)
Royan InstituteSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
9 Active assets in the Parkinson Disease (PD) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
18f-mfbg Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | Phase 2 | CCC |
Vgn-R08B Shanghai Vitalgen BioPharma Co., Ltd. | Phase 1/2 | CC |
18f-op-801 Ashvattha Therapeutics, Inc. | Phase 1/2 | CC |
Everolimus Royan Institute | Phase 1 | CC |
Dopacell Royan Institute | Phase 1 | CC |
View all 9 →
Same molecule, other indications
Monomethyl Fumarate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →